The BASILICA Trial: Prospective Multicenter Investigation of Intentional Leaflet Laceration to Prevent TAVR Coronary Obstruction
The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study. Coronary artery obstruction is a rare but devasta...
Saved in:
Published in | JACC. Cardiovascular interventions Vol. 12; no. 13; pp. 1240 - 1252 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
08.07.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study.
Coronary artery obstruction is a rare but devastating complication of transcatheter aortic valve replacement (TAVR). Current stent-based preventative strategies are suboptimal. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a novel transcatheter technique performed immediately before TAVR to prevent coronary artery obstruction.
Subjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and at high risk of coronary artery obstruction, were included. The primary success endpoint was successful BASILICA and TAVR without coronary obstruction or reintervention. The primary safety endpoint was freedom from major adverse cardiovascular events. Data were independently monitored. Endpoints were independently adjudicated. A core laboratory analyzed computed tomography images.
Between February 2018 and July 2018, 30 subjects were enrolled. Primary success was met in 28 (93%) subjects. BASILICA traversal and laceration was successful in 35 of 37 (95%) attempted leaflets. There was 100% freedom from coronary obstruction and reintervention. Primary safety was met in 21 (70%), driven by 6 (20%) major vascular complications related to TAVR but not BASILICA. There was 1 death at 30 days. There was 1 (3%) disabling stroke and 2 (7%) nondisabling strokes. Transient hemodynamic compromise was rare (7%) and resolved promptly with TAVR.
BASILICA was feasible in both native and bioprosthetic valves. Hemodynamic compromise was uncommon. Safety was acceptable and needs confirmation in larger studies. BASILICA appears effective in preventing coronary artery obstruction from TAVR in subjects at high risk. |
---|---|
AbstractList | The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study.OBJECTIVESThe BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study.Coronary artery obstruction is a rare but devastating complication of transcatheter aortic valve replacement (TAVR). Current stent-based preventative strategies are suboptimal. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a novel transcatheter technique performed immediately before TAVR to prevent coronary artery obstruction.BACKGROUNDCoronary artery obstruction is a rare but devastating complication of transcatheter aortic valve replacement (TAVR). Current stent-based preventative strategies are suboptimal. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a novel transcatheter technique performed immediately before TAVR to prevent coronary artery obstruction.Subjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and at high risk of coronary artery obstruction, were included. The primary success endpoint was successful BASILICA and TAVR without coronary obstruction or reintervention. The primary safety endpoint was freedom from major adverse cardiovascular events. Data were independently monitored. Endpoints were independently adjudicated. A core laboratory analyzed computed tomography images.METHODSSubjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and at high risk of coronary artery obstruction, were included. The primary success endpoint was successful BASILICA and TAVR without coronary obstruction or reintervention. The primary safety endpoint was freedom from major adverse cardiovascular events. Data were independently monitored. Endpoints were independently adjudicated. A core laboratory analyzed computed tomography images.Between February 2018 and July 2018, 30 subjects were enrolled. Primary success was met in 28 (93%) subjects. BASILICA traversal and laceration was successful in 35 of 37 (95%) attempted leaflets. There was 100% freedom from coronary obstruction and reintervention. Primary safety was met in 21 (70%), driven by 6 (20%) major vascular complications related to TAVR but not BASILICA. There was 1 death at 30 days. There was 1 (3%) disabling stroke and 2 (7%) nondisabling strokes. Transient hemodynamic compromise was rare (7%) and resolved promptly with TAVR.RESULTSBetween February 2018 and July 2018, 30 subjects were enrolled. Primary success was met in 28 (93%) subjects. BASILICA traversal and laceration was successful in 35 of 37 (95%) attempted leaflets. There was 100% freedom from coronary obstruction and reintervention. Primary safety was met in 21 (70%), driven by 6 (20%) major vascular complications related to TAVR but not BASILICA. There was 1 death at 30 days. There was 1 (3%) disabling stroke and 2 (7%) nondisabling strokes. Transient hemodynamic compromise was rare (7%) and resolved promptly with TAVR.BASILICA was feasible in both native and bioprosthetic valves. Hemodynamic compromise was uncommon. Safety was acceptable and needs confirmation in larger studies. BASILICA appears effective in preventing coronary artery obstruction from TAVR in subjects at high risk.CONCLUSIONSBASILICA was feasible in both native and bioprosthetic valves. Hemodynamic compromise was uncommon. Safety was acceptable and needs confirmation in larger studies. BASILICA appears effective in preventing coronary artery obstruction from TAVR in subjects at high risk. The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study. Coronary artery obstruction is a rare but devastating complication of transcatheter aortic valve replacement (TAVR). Current stent-based preventative strategies are suboptimal. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a novel transcatheter technique performed immediately before TAVR to prevent coronary artery obstruction. Subjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and at high risk of coronary artery obstruction, were included. The primary success endpoint was successful BASILICA and TAVR without coronary obstruction or reintervention. The primary safety endpoint was freedom from major adverse cardiovascular events. Data were independently monitored. Endpoints were independently adjudicated. A core laboratory analyzed computed tomography images. Between February 2018 and July 2018, 30 subjects were enrolled. Primary success was met in 28 (93%) subjects. BASILICA traversal and laceration was successful in 35 of 37 (95%) attempted leaflets. There was 100% freedom from coronary obstruction and reintervention. Primary safety was met in 21 (70%), driven by 6 (20%) major vascular complications related to TAVR but not BASILICA. There was 1 death at 30 days. There was 1 (3%) disabling stroke and 2 (7%) nondisabling strokes. Transient hemodynamic compromise was rare (7%) and resolved promptly with TAVR. BASILICA was feasible in both native and bioprosthetic valves. Hemodynamic compromise was uncommon. Safety was acceptable and needs confirmation in larger studies. BASILICA appears effective in preventing coronary artery obstruction from TAVR in subjects at high risk. |
Author | Lederman, Robert J Satler, Lowell Leshnower, Bradley G Reisman, Mark Chen, Marcus Y Dvir, Danny Rogers, Toby Khan, Jaffar M Eng, Marvin H Waksman, Ron Stine, Annette M Babaliaros, Vasilis C Paone, Gaetano Tian, Xin Greenbaum, Adam B |
AuthorAffiliation | d Medstar Washington Hospital Center, Washington, DC e University of Washington, Seattle, Washington c Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia b Center for Structural Heart Disease, Division of Cardiology, and Division of Cardiac Surgery, Henry Ford Health System, Detroit, Michigan a Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maiyland |
AuthorAffiliation_xml | – name: a Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maiyland – name: c Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia – name: b Center for Structural Heart Disease, Division of Cardiology, and Division of Cardiac Surgery, Henry Ford Health System, Detroit, Michigan – name: e University of Washington, Seattle, Washington – name: d Medstar Washington Hospital Center, Washington, DC |
Author_xml | – sequence: 1 givenname: Jaffar M surname: Khan fullname: Khan, Jaffar M organization: Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland – sequence: 2 givenname: Adam B surname: Greenbaum fullname: Greenbaum, Adam B organization: Center for Structural Heart Disease, Division of Cardiology, and Division of Cardiac Surgery, Henry Ford Health System, Detroit, Michigan; Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia – sequence: 3 givenname: Vasilis C surname: Babaliaros fullname: Babaliaros, Vasilis C organization: Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia – sequence: 4 givenname: Toby surname: Rogers fullname: Rogers, Toby organization: Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; Medstar Washington Hospital Center, Washington, DC – sequence: 5 givenname: Marvin H surname: Eng fullname: Eng, Marvin H organization: Center for Structural Heart Disease, Division of Cardiology, and Division of Cardiac Surgery, Henry Ford Health System, Detroit, Michigan – sequence: 6 givenname: Gaetano surname: Paone fullname: Paone, Gaetano organization: Center for Structural Heart Disease, Division of Cardiology, and Division of Cardiac Surgery, Henry Ford Health System, Detroit, Michigan – sequence: 7 givenname: Bradley G surname: Leshnower fullname: Leshnower, Bradley G organization: Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia – sequence: 8 givenname: Mark surname: Reisman fullname: Reisman, Mark organization: University of Washington, Seattle, Washington – sequence: 9 givenname: Lowell surname: Satler fullname: Satler, Lowell organization: Medstar Washington Hospital Center, Washington, DC – sequence: 10 givenname: Ron surname: Waksman fullname: Waksman, Ron organization: Medstar Washington Hospital Center, Washington, DC – sequence: 11 givenname: Marcus Y surname: Chen fullname: Chen, Marcus Y organization: Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland – sequence: 12 givenname: Annette M surname: Stine fullname: Stine, Annette M organization: Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland – sequence: 13 givenname: Xin surname: Tian fullname: Tian, Xin organization: Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland – sequence: 14 givenname: Danny surname: Dvir fullname: Dvir, Danny organization: University of Washington, Seattle, Washington – sequence: 15 givenname: Robert J surname: Lederman fullname: Lederman, Robert J email: lederman@nih.gov organization: Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: lederman@nih.gov |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31202947$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkN9LwzAQx4Mozqn_gA-SR182kzRLGx-EOfwxqEy0-lrS9Dozuqam6cA3_3QjU1E4yF3uw_d7d0O029gGEDqhZEwJFeer8UqbZswIlWMShZjsoAOaxGIUCzLZ_ZMP0LDrVoQIImO2jwYRZYRJHh-gj-wV8NX0aZ7OZ1OcOaPqC_zgbNeC9mYD-L6vvdHQeHB43myg82apvLENtlX48KETClXjFFRVg8ep0uC2hLdBCjYBwdn05RHPrAuoe8eLovOu11_QEdqrVN3B8fd7iJ5vrrPZ3Shd3IaR0lHLhPAjDVyUPOY8LEF5UUxkKSaa06IokoQJSCSwqiqBlIUCkDHEkislGKU60gBxdIgut7ptX6yh_NrIqTpvnVmHiXKrTP6_05jXfGk3uRBCJjIKAmffAs6-9eEO-dp0GupaNWD7LmeMBzfGIhbQ079evyY_Z48-AYWpiuE |
ContentType | Journal Article |
Copyright | Published by Elsevier Inc. |
Copyright_xml | – notice: Published by Elsevier Inc. |
DBID | CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1016/j.jcin.2019.03.035 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1876-7605 |
EndPage | 1252 |
ExternalDocumentID | PMC6669893 31202947 |
Genre | Multicenter Study Research Support, N.I.H., Intramural Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | United States |
GeographicLocations_xml | – name: United States |
GrantInformation_xml | – fundername: Intramural NIH HHS grantid: ZIA HL006040 |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 18M 1B1 1P~ 1~. 4.4 457 4G. 53G 5GY 5VS 7-5 8P~ AAEDW AAIKJ AALRI AAOAW AAQFI AAXUO AAYWO ABBQC ABFRF ABJNI ABMAC ABMZM ACGFO ACGFS ADBBV ADEZE ADVLN AEFWE AEKER AEVXI AEXQZ AFCTW AFETI AFJKZ AFRHN AFTJW AGCQF AGYEJ AITUG AJRQY ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BLXMC CGR CS3 CUY CVF DIK EBS ECM EFKBS EIF EJD F5P FDB FEDTE FNPLU GBLVA HVGLF IXB J1W M41 MO0 N9A NPM O-L O9- OAUVE OA~ OK1 OL0 P-8 P-9 P2P PC. Q38 RIG ROL SDF SEL SES SSZ W8F Z5R 7X8 5PM |
ID | FETCH-LOGICAL-p266t-ce46d474400614bb59d65c41bbb8826e89e2ffde0dbaee97e794aa6211c3cee73 |
ISSN | 1876-7605 1936-8798 |
IngestDate | Thu Aug 21 18:23:55 EDT 2025 Fri Jul 11 02:53:12 EDT 2025 Mon Jul 21 06:02:54 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 13 |
Keywords | coronary artery obstruction transcatheter aortic valve replacement transcatheter electrosurgery bioprosthetic heart valve failure structural heart disease |
Language | English |
License | Published by Elsevier Inc. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p266t-ce46d474400614bb59d65c41bbb8826e89e2ffde0dbaee97e794aa6211c3cee73 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 Dr. Rogers has served as a consultant for Medtronic; and a physician proctor for Edwaids Lifesdences and Medtronic. Drs. Eng and Paone have served as proctors for Edwaids Lifesdences. Dr. Leshnower has served on the Medtronic Speakers Bureau. Dr. Waksman has served on the advisory board for Abbott Vasculai, Amgen, Boston Sdentific, Caidioset, Caidiovasculai Systems, Medtronic, Philips Volcano, and Pi-Cardia; has served as a consultant for Abbott Vasculai, Amgen, Boston Sdentific, Biotronik, Biosensors, Cardioset, Cardiovascular Systems, Philips Volcano, Pi-Cardia, and Medtronic; has received grant support from Abbott Vascular, AstraZeneca, Boston Sdentific, and Chiesi; has served on the Speakers Bureau for AstraZeneca and Chiesi; and is an investor in MedAlliance. Dr. Dvir has served as a consultant for Edwards Lifesdences, Medtronic, and Abbott Vascular. Drs. Khan, Rogers, and Lederman aie co-inventois on patents, assigned to the National Institutes of Health, on cathetei devices to lacerate valve leaflets. All other authors have reported that they have no relationships relevant to the contents of this paper to disdose. Lais Soendergaard, MD, served as the Guest Editor for this paper. |
PMID | 31202947 |
PQID | 2242112232 |
PQPubID | 23479 |
PageCount | 13 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6669893 proquest_miscellaneous_2242112232 pubmed_primary_31202947 |
PublicationCentury | 2000 |
PublicationDate | 2019-07-08 |
PublicationDateYYYYMMDD | 2019-07-08 |
PublicationDate_xml | – month: 07 year: 2019 text: 2019-07-08 day: 08 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | JACC. Cardiovascular interventions |
PublicationTitleAlternate | JACC Cardiovasc Interv |
PublicationYear | 2019 |
References | 31202952 - JACC Cardiovasc Interv. 2019 Jul 8;12(13):1253-1255. doi: 10.1016/j.jcin.2019.04.009. |
References_xml | – reference: 31202952 - JACC Cardiovasc Interv. 2019 Jul 8;12(13):1253-1255. doi: 10.1016/j.jcin.2019.04.009. |
SSID | ssj0060972 |
Score | 2.6256058 |
Snippet | The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational... |
SourceID | pubmedcentral proquest pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 1240 |
SubjectTerms | Aged Aged, 80 and over Aortic Valve - diagnostic imaging Aortic Valve - physiopathology Aortic Valve - surgery Aortic Valve Stenosis - diagnostic imaging Aortic Valve Stenosis - physiopathology Aortic Valve Stenosis - surgery Bioprosthesis Coronary Stenosis - diagnostic imaging Coronary Stenosis - etiology Coronary Stenosis - physiopathology Coronary Stenosis - prevention & control Feasibility Studies Female Heart Valve Prosthesis Heart Valve Prosthesis Implantation - adverse effects Heart Valve Prosthesis Implantation - instrumentation Hemodynamics Humans Iatrogenic Disease - prevention & control Male Prospective Studies Prosthesis Design Prosthesis Failure Risk Factors Time Factors Transcatheter Aortic Valve Replacement - adverse effects Transcatheter Aortic Valve Replacement - instrumentation Treatment Outcome United States |
Title | The BASILICA Trial: Prospective Multicenter Investigation of Intentional Leaflet Laceration to Prevent TAVR Coronary Obstruction |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31202947 https://www.proquest.com/docview/2242112232 https://pubmed.ncbi.nlm.nih.gov/PMC6669893 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwELZYkBAXxGPZLS8VaW9VosRJnOTYBhAPFa3YgrhVduwsRTSt2nKAX89MnBSn6gG4RFXc1nK-0fgbZ-YbQv5IKQLPka6lOMSqPgTMVgTbuJUxz1NOwKOoqJDr3rCLO__qIXgwKq6xumQm7PRtaV3Jd1CFe4ArVsl-Adn5n8IN-Az4whUQhuunMe60_11iOXCrhxPWuGY7SWzM6KglnBo5jh_vcR71MegVzzLU9bFrWTmC617IbcmHrc58rMMFnpFMdJ7ePZ8OngfTVjIfvx39L_uv9Ubi1TxdKAqaLMd0iDEKFoe6U7St9D3woFbInKDmRalpLZ7hE4FBOMb-CoyKLvXd-hjhyX5KByhM62r1WS1mYoA5HhZoei51aKzVOhcUs_92EwjKYmBiP8gahfABO1ucXl5XOzRDySKdbaDXVhZT6by_xek3yHo117IoZDGZ1mAnvS2yWYYVzba2kW2yovIdst4tEyd2yTaYSrMylWZhKj_J3flZL7mwynYY1hhY1MxKlc-kj4KOGMULEcSSBanvCiEgTGIqihXNMqkcKbhScajA1XLOIMJPPaBCobdHVvNRrn6Tpod9CICYAD3JfJGGcepEikrOMjdkKY0a5KRaaB_cDb5D4rkavUz7FFMIXOCUtEF-6YX3x1oXpV89pgYJa49k_gWUMq-P5IPHQtK8xGv_2788IBsf5ntIVmeTF3UEdHEmjgvs3wHCHWRM |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+BASILICA+Trial&rft.jtitle=JACC.+Cardiovascular+interventions&rft.au=Khan%2C+Jaffar+M.&rft.au=Greenbaum%2C+Adam+B.&rft.au=Babaliaros%2C+Vasilis+C.&rft.au=Rogers%2C+Toby&rft.date=2019-07-08&rft.issn=1936-8798&rft.eissn=1876-7605&rft.volume=12&rft.issue=13&rft.spage=1240&rft.epage=1252&rft_id=info:doi/10.1016%2Fj.jcin.2019.03.035&rft_id=info%3Apmid%2F31202947&rft.externalDocID=PMC6669893 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1876-7605&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1876-7605&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1876-7605&client=summon |